Table 4 Sorafenib-related adverse events.

From: Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients

 

Count

%

Hypertension

87

12.3

Hypertension Grade

1

64

9.1

2

18

2.5

3

5

0.7

Hand and foot syndrome

31

4.4

Hand and foot syndrome Grade

1

16

2.3

2

10

1.4

3

5

0.7

Skin lesions

92

13.0

Skin lesions Grade

1

63

8.9

2

25

3.5

3

4

0.6

Diarrhea

56

7.9

Diarrhea Grade

1

45

6.4

2

10

1.4

3

1

0.1

Fatigue

174

24.6

Fatigue Grade

1

146

20.7

2

22

3.1

3

6

0.8

Abdominal pain

76

10.8

Abdominal pain Grade

1

66

9.3

2

5

0.7

3

3

0.4

4

2

0.3

Jaundice

218

30.9

Jaundice Grade

1

116

16.4

2

82

11.6

3

20

2.8

Anemia

136

19.3

Elevated liver enzymes

109

15.4

Ascites

47

6.7

Nausea/vomiting

27

3.8

Hepatic encephalopathy

26

3.7

Hematemesis

14

2.0

Other side effects

Renal impairment

14

1.9

DCL

8

1.1

Anorexia

6

0.8

Myocardial ischemia

5

0.7

Hypothyroidism

4

0.6

Fever

3

0.4

Arrhythmia

2

0.2

Dysphonia (vocal cord edema)

2

0.2

Alopecia

2

0.3

Hoarseness of voice

2

0.2

Leucopenia

2

0.3

Peripheral neuropathy

2

0.2

Altered taste

1

0.1

Bleeding gums

1

0.1

Chest tightness

1

0.1

Glossitis

1

0.1

Hair loss and whitening

1

0.1

Melena

1

0.1

Myocardial infarction

1

0.1

Pancytopenia

1

0.1

Recurrent hypoglycemia

1

0.1

Severe bone pain

1

0.1%

Steven Johnson Syndrome

1

0.1

Subacute DVT

1

0.1

Back to article page